Adenoviral vectors: Systemic delivery and tumor targeting

Cancer Gene Therapy

Volumn 9, Issue 12, 2002, Pages 1036-1042

  Green, Nicola K ^a   Seymour, Leonard W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenovirus; Gene delivery; Gene therapy; Pharmacokinetics; Tumor targeting; Virus retargeting

Indexed keywords

ADENOVIRUS DEATH PROTEIN; ADENOVIRUS VECTOR; CN 706; GENE PRODUCT; LIVER ENZYME; MACROGOL; NEUTRALIZING ANTIBODY; ONYX 015; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEIN MDM2; PROTEIN P53; SURFACTANT PROTEIN B; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COXSACKIE VIRUS; DISEASE MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; DRY EYE; FEVER; GENE EXPRESSION REGULATION; GENE LOCUS; GENE MUTATION; HEPATITIS; HUMAN; IMMUNE RESPONSE; LIVER CANCER; LIVER TOXICITY; LUNG CANCER; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR BINDING; REVIEW; RIGOR; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; ANTIBODY SPECIFICITY; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; METHODOLOGY; NEOPLASM; PHYSIOLOGY; TISSUE DISTRIBUTION; VIROLOGY;

ADENOVIRIDAE; COXSACKIEVIRUS;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; ORGAN SPECIFICITY; PROMOTER REGIONS (GENETICS); TISSUE DISTRIBUTION; VIRUS REPLICATION;

EID: 0036901290     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700541     Document Type: Review

References (59)

1. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol. 2000;81:2605-2609.
2. Tao N, Gao GP, Parr M, et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther. 2001;3:28-35.
3. Ye X, Jerebtsova M, Ray PE. Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum Gene Ther. 2000;11:621-627.
4. Vlachaki MT, Hernandez-Garcia A, Ittmann M, et al. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol Ther. 2002;6:342-348.
5. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
6. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalisation but not virus attachment. Cell. 1993;73:309-319.
7. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology. 2000;268:382-390.
8. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol. 2001;75:8772-8780.
9. Bergelson JM, Krithivas A, Celi L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol. 1998;72:415-419.
10. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 2001;8:1347-1353.
11. Leissner P, Legrand V, Schlesinger Y, et al. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther. 2001;8:49-57.
12. Smith T, Idamakanti N, Kylefjord H, et al. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther. 2002;5:770-779.
13. Einfeld DA, Schroeder R, Roelvink PW, et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol. 2001;75:11284-11291.
14. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol. 1996;14:1574-1578.
15. Wickham TJ, Lee GM, Titus JA, et al. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol. 1997;71:7663-7669.
16. Wickham TJ, Haskard D, Segal D, Kovesdi I. Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol Immunother. 1997;45:149-151.
17. Goldman CK, Rogers BE, Douglas JT, et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 1997;57:1447-1451.
18. Rancourt C, Rogers BE, Sosnowski BA, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res. 1998;4:2455-2461.
19. Blackwell JL, Miller CR, Douglas JT, et al. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1999;125:856-863.
20. Nicklin SA, White SJ, Watkins SJ, Hawkins RE, Baker AH. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation. 2000;102:231-237.
21. McDonald GA, Zhu G, Li Y, Kovesdi I, Wickham TJ, Sukhatme VP. Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector. J Gene Med. 1999;1:103-110.
22. Kasono K, Blackwell JL, Douglas JT, et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res. 1999;5:2571-2579.
23. Vanderkwaak TJ, Wang M, Gomez-Navarro J, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol. 1999;74:227-234.
24. Printz MA, Gonzalez AM, Cunningham M, et al. Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther. 2000;11:191-204.
25. Reynolds PN, Zinn KR, Gavrilyuk VD, et al. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther. 2000;2:562-578.
26. Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O'Riordan CR. Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice. Hum Gene Ther. 1999;10:2615-2626.
27. Drapkin PT, O'Riordan CR, Yi SM, et al. Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J Clin Invest. 2000;105:589-596.
28. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001;8:341-348.
29. Green NK, Hale SJ, Fasci CA, Fisher KD, Mautner V, Seymour LW. Polymer modification of adenoviral vectors for systemic gene delivery. J Gene Med. 2001 (published abstracts from the 9th meeting of the European Society for Gene Therapy).
30. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 1987;156:107-121.
31. Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
32. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol. 1998;72:9479-9490.
33. Rothman T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol. 1998;72:9470-9478.
34. Turnell AS, Grand RJ, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol. 1999;73:2074-2083.
35. Bates S, Phillips AC, Clark PA, et al. p14ARF links the tumour suppressors RB and p53. Nature. 1998;395:124-125.
36. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev. 2000;10:94-99.
37. Ries SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat Med. 2000;6:1128-1133.
38. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000;74:6147-6155.
39. Bohinski RJ, Di Lauro R, Whitsett JA. The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol Cell Biol. September 1994;14:5671-5681.
40. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol. 2001;75:3314-3324.
41. Habib NA, Mitry R, Seth P, et al. Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther. 2002;9:651-654.
42. Jelsma TN, Howe JA, Mymryk JS, Evelegh CM, Cunniff NF, Bayley ST. Sequences in E1A proteins of human adenovirus 5 required for cell transformation, repression of a transcriptional enhancer, and induction of proliferating cell nuclear antigen. Virology. 1989;171:120-130.
43. Fueyo J, Gomez-Manzano C, Alemany R. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19:2-12.
44. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000;6:1134-1139.
45. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
46. Simons JW, Mikhak B, Van Der Poel HG, et al. Molecular and clinical activity of CN706, a PSA-selective oncolytic AD5 vector in a phase I trial in locally recurrent prostate cancer following radiation therapy. Mol Ther. 2000;1:S144-S145.
47. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther. 1999;10:1721-1733.
48. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest. 2000;106:763-771.
49. Ganly I, Kim D, Eckhardt SG, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumourally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6:798-806.
50. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Ther. 2001;8:308-315.
51. Batshaw ML, Wilson JM, Raper S, Yudkoff M, Robinson MB. Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). Hum Gene Ther. 1999;10:2419-2437.
52. Miller D. Gene therapy on trial. Science. 2000;288:951-957.
53. Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther. 2001;3:697-707.
54. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 1996;3:137-144.
55. + CTLs in vivo. J Immunol. 1995;155:2564-2570.
56. Cichon G, Boeckh-Herwig S, Schmidt HH, et al. Complement activation by recombinant adenoviruses. Gene Ther. 2001;8:1794-1800.
57. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther. 2001;8:1618-1626.
58. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther. 2001;8:746-759.
59. Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 1999;6:57-62.